Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance Therapy After ASCT for Multiple Myeloma
NCT00114101Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2004
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenalidomide in multiple myeloma (MM), sponsored by National Cancer Institute. Started Dec 2004; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00114101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114101.